School of Medicine


Showing 51-100 of 153 Results

  • Neel K. Gupta

    Neel K. Gupta

    Clinical Assistant Professor, Medicine - Oncology
    Clinical Assistant Professor, Medicine - Hematology

    Current Research and Scholarly InterestsI have specific interest in the pathobiology and management of individuals with AIDS-related and primary central nervous system lymphomas.

  • Tanya Gupta, MD

    Tanya Gupta, MD

    Clinical Assistant Professor, Medicine - Oncology

    BioDr. Gupta is a medical oncologist in the Stanford University Department of Medicine, Division of Medical Oncology. In her clinical practice and research, she is dedicated to advancing the understanding and management of breast cancer.

    She is a recent recipient of the American Society of Clinical Oncology (ASCO)/Conquer Cancer 2020 Bonadonna Breast Cancer Research Grant. This grant supports her work as the co-investigator of a clinical trial evaluating the ctDNA status changes during adjuvant treatment of patients with early-stage triple-negative breast cancer who do not respond completely to neoadjuvant chemotherapy.

    Dr. Gupta was a member of the combined bachelors/MD program at the University of California – San Diego. She graduated summa cum laude and was inducted into the Gold Humanism in Medicine Honor Society. She completed internship and residency in Internal Medicine at Stanford, during which time she was a recipient of the Julian Wolfsohn Award for clinical achievements in Internal Medicine and was inducted into the Alpha Omega Alpha Honor Medical Society. She then served as a Chief Resident and Clinical Instructor in Internal Medicine. Subsequently, she stayed on at Stanford for fellowship training in Hematology and Medical Oncology.

  • Gregory M. Heestand, MD

    Gregory M. Heestand, MD

    Clinical Associate Professor, Medicine - Oncology

    BioDr. Heestand is a board-certified medical oncologist with a focus on gastrointestinal cancers, primarily hepatocellular carcinoma, cholangiocarcinoma, and gallbladder cancer. He currently serves as the medical oncology champion of the Stanford Hepatobiliary Tumor Board, as well as the principal investigator of multiple clinical trials. He also collaborates with campus laboratories to help develop new biomarker and treatment technologies. Dr. Heestand is a member of the ECOG-ACRIN gastrointestinal committee and serves as a representative to the NCI Hepatobiliary Task Force. He is also the director of the Stanford Medical Oncology Fellowship Program.

    Dr. Heestand and his team take great pride in helping patients and their families face gastrointestinal cancer.

    Outside of the clinic, Dr. Heestand enjoys playing the piano, teaching his kids about music, cooking for friends and family, and surfing the internet for interesting things to read.

  • Christian Hoerner

    Christian Hoerner

    Sr Research Scientist-Basic Life, Medicine - Med/Oncology

    Current Role at StanfordStaff Scientist and Lab Manager, Alice Fan Lab

  • Thomas Holden, MD

    Thomas Holden, MD

    Clinical Assistant Professor, Medicine - Oncology

    BioDr. Holden is a board-certified, fellowship-trained medical oncologist. He is a Clinical Assistant Professor at Stanford University School of Medicine.

    He specializes in care for people with gastrointestinal cancer including those of the colon, rectum, esophagus, liver, pancreas, and stomach. Dr. Holden works closely with patients to prepare personalized, comprehensive, and compassionate care plans that optimize healing and quality of life.

    Dr. Holden has conducted research into a wide range of subjects. He co-developed and established a multi-center trial investigating a new treatment regimen for gastric cancer. He has studied use of a fitness tracker to assess activity levels and toxicities in patients with colorectal cancer. He also has written invited commentary on the rapidly advancing field of genetic testing as well as a review on recent updates on the treatment of early-stage rectal cancer.

    He has published his research findings in articles in peer-reviewed journals including JAMA, the Journal of Clinical Oncology, Cortex, and elsewhere. He has made poster presentations to his peers at meetings including the ASCO Gastrointestinal Cancers symposium and House Staff Quality Improvement and Patient Safety Conference, a meeting held annually at Thomas Jefferson University.

    Dr. Holden has volunteered his time and expertise to help improve access to health care for homeless and underserved populations.

    In his free time, he runs, reads, plays the acoustic guitar, and travels.

  • Sandra Horning

    Sandra Horning

    Professor of Medicine, Emerita

    Current Research and Scholarly InterestsClinical Interests: Hodgkin's disease and non-Hodgkin's lymphoma. Research Interests: clinical trials in Hodgkin's disease and malignant lymphoma including high dose therapy and autografting, complications of cytotoxic therapy, novel therapeutics, and clinicopathologic correlations.

  • Robert Hsieh

    Robert Hsieh

    Adjunct Clinical Assistant Professor, Medicine - Oncology

    BioRobert W. Hsieh, M.D. Ph.D. is a medical oncologist who specializes in the treatment of prostate cancer, bladder cancer, kidney (renal) cancer and testicular cancer as a member of Stanford's multi-disciplinary Urologic Cancer Program. Dr. Hsieh obtained his M.D. and Ph.D. degrees at the University of Chicago (Pritzker School of Medicine) and subsequently came to Stanford to complete his Internal Medicine residency and Hematology and Oncology fellowship training (with a clinical focus on genitourinary cancers).

    Dr. Hsieh has also had extensive experience in basic lab research (cancer stem cells, target identification and validation, pre-clinical drug discovery) having done post-doctoral work in the Clarke Lab in the Institute for Stem Cell Biology and Regenerative Medicine. He is currently involved in early phase clinical trials in immuno-oncology in industry.

  • Haruka Itakura

    Haruka Itakura

    Assistant Professor of Medicine (Oncology)

    BioDr. Itakura is an Assistant Professor of Medicine (Oncology) in the Stanford University School of Medicine and practicing oncologist at the Stanford Cancer Center with background in biomedical informatics. She is a physician-scientist whose research mission is to drive medical advances at the intersection of cancer and data science research. Specifically, she aims to innovate state-of-the-art technologies to extract clinically useful knowledge from heterogeneous multi-scale biomedical data to improve diagnostics and therapeutics in cancer. She is a board-certified hematologist-oncologist and informaticist with specialized training in basic science, health services, and translational research. Her clinical background in oncology and PhD training in Biomedical Informatics position her to develop and apply data science methodologies on heterogeneous, multi-scale cancer data to extract actionable knowledge that can improve patient outcomes. Her ongoing research to develop and apply cutting-edge knowledge and skills to pioneer new robust methodologies for analyzing cancer big data is being supported by an NIH K01 Career Development Award in Biomedical Big Data Science. Her research focuses on developing and applying machine learning frameworks and radiogenomic approaches for the integrative analysis of heterogeneous, multi-scale data to accelerate discoveries in cancer diagnostics and therapeutics. Projects include prediction modeling of survival and treatment response, biomarker discovery, cancer subtype discovery, and identification of new therapeutic targets.

  • Charlotte D. Jacobs M.D.

    Charlotte D. Jacobs M.D.

    Drs. Ben and A. Jess Shenson Professor in the School of Medicine, Emerita

    Current Research and Scholarly InterestsClinical Interests: general oncology, sarcomas. Research Interests: clinical trials in solid tumors.

  • Hanlee P. Ji

    Hanlee P. Ji

    Professor of Medicine (Oncology) and, by courtesy of Electrical Engineering

    Current Research and Scholarly InterestsCancer genomics and genetics, translational applications of next generation sequencing technologies, development of molecular signatures as prognostic and predictive biomarkers in oncology, primary genomic and proteomic technology development, cancer rearrangements, genome sequencing, big data analysis

  • Esther M. John

    Esther M. John

    Professor (Research) of Epidemiology and Population Health and of Medicine (Oncology)

    Current Research and Scholarly InterestsDr. John has extensive expertise in conducting population-based epidemiologic studies and has led as Principal Investigator multiple large-scale studies, including multi-center studies with a study site in the San Francisco Bay Area with its diverse population. Many of her studies and collaborations investigated cancer health disparities. Her research has focused on the role of modifiable lifestyle factors (e.g., body size, physical activity, diet), hormonal factors, early-life exposures, genetic variants, and gene-environment interactions; differences in risk factors by race/ethnicity, breast cancer subtypes, and prostate cancer subtypes; risk factors for familial breast cancer and second primary breast cancer, as well as prognostic factors related to survival disparities.

    As Principal Investigator, Dr. John has led a number of studies conducted in the San Francisco Bay Area, including:

    - the Northern California site of the Breast Cancer Family Registry, an on-going prospective multi-generational cohort of over 13,000 families established in 1995 at six international sites;
    - the Northern California site of the WECARE Study that investigates risk factors for second primary breast cancer;
    - the California site of the Breast Cancer Health Disparities Study that investigated genetic variability and breast cancer risk and survival in Hispanic and non-Hispanic white populations in the context of genetic admixture;
    - the Breast Cancer Etiology in Minorities (BEM) Study, a pooled analysis of risk factors for breast cancer subtypes in racial/ethnic minorities;
    - the San Francisco Bay Area Breast Cancer Study, a population-based case-control study in nearly 5,000 Hispanic, African American and non-Hispanic white women that investigated the role of modifiable lifestyle factors and other risk factors;
    - the San Francisco Bay Area Prostate Cancer Study, a population-based case-control study of lifestyle and genetic risk factors for advanced and localized disease.

    These studies collected and pooled extensive data and biospecimens and continue to support numerous ancillary studies, collaborations and international consortia and have contributed to a better understanding of cancer risk and survival in racial/ethnic minority populations.

    Dr. John is also a founding PI of the LEGACY Girls Study, an on-going prospective cohort established in 2011 that investigates early life exposures in relation to pubertal development outcomes, breast tissue characteristics, and behavioral and psychosocial outcomes in the context of having a family history or breast cancer.

  • Tyler Johnson

    Tyler Johnson

    Clinical Assistant Professor, Medicine - Oncology

    BioDr. Tyler Johnson is a physician, author, educator, and humanitarian. At the Stanford University School of Medicine, he has held an appointment as a clinical assistant professor for six years. A medical oncologist, Dr. Johnson sees patients with all types of gastrointestinal malignancies and particularly focuses on patients with neuroendocrine tumors, colon cancer, and pancreas cancer.

    Dr. Johnson also serves as a leader of the Stanford inpatient oncology services, including supervising the oncology housestaff service. He is responsible, in conjunction with other leaders, for multiple major improvements in the functioning of Stanford hospital.

    Dr. Johnson views the practice of medicine largely as an educational endeavor. To that end, for many years he has taught medical students, residents, and fellows—including hosting them as temporary and longer-term apprentices in his oncology clinic and working with them on the inpatient housestaff oncology service. He emphasizes diversity and inclusion in his mentoring efforts and has worked tirelessly to promote the professional development of medical trainees across the training spectrum--from undergraduates to oncology fellows.

    The winner of multiple Stanford Medicine teaching awards, Dr. Johnson has established himself as a regional and increasingly as a national leader and innovator in the education of oncology fellows, including by developing novel teaching methods that have been presented across the country, including at national meetings. He also heads the Stanford oncology department’s curricular development and as part of that had developed a novel curricular approach that centers the needs and teaching abilities of oncology fellows. He also works as one of the principal faculty members of the Stanford Educators-4-CARE program.

    Dr. Johnson and his co-host, Henry Bair, became concerned about the loss of a shared sense of meaning in the medical profession and, together, have taught multiple classes in the Medical School and, in the spring of 2022, founded The Doctor's Art podcast. Over the remainder of 2022, this podcast became one of the five most listened-to medical podcasts in the nation, with a growing national and international listenership.

    Finally, Dr. Johnson is an author with a growing reputation for insightful analysis of the intersection of medicine, ethics, and spirituality. His writings has been featured by Religion News Service, the Salt Lake Tribune, BYU Studies, Dialogue, and The San Jose Mercury News, where he is a regular contributor.

  • Vishnu Priya Kanakaveti

    Vishnu Priya Kanakaveti

    Postdoctoral Scholar, Oncology

    Current Research and Scholarly InterestsI am interested in elucidating molecular mechanisms of MYC-driven drug resistance and immune evasion in cancer using computational and experimental models.

  • Ali Raza Khaki, MD

    Ali Raza Khaki, MD

    Clinical Assistant Professor, Medicine - Oncology

    BioDr. Khaki is a medical oncologist and clinical assistant professor at Stanford University School of Medicine.

    In his clinical practice, he treats patients with all forms of genitourinary cancer, including kidney, bladder, prostate, and testicular. He also regularly attends on the inpatient oncology service at Stanford Hospital.
    With each patient, he is devoted to providing exceptional, humanistic care and has been recognized throughout his career for his humanism. As a medical student, he was named to the national Gold Humanism Honor Society and he received the Reza Gandjei Humanism Award as a medical resident at UCSF.

    His research interests include novel therapies for genitourinary cancers, with a focus on urothelial cancer outcomes. He also has studied health care utilization and costs for end-of-life care of cancer patients.

    Dr. Khaki has earned honors and recognition from the American Association for Cancer Research, American Society of Clinical Oncology, Bladder Cancer Advocacy Network, Conquer Cancer Foundation, and other organizations.

    He has authored numerous articles on topics such as immunotherapy for urothelial cancer, management of cancer patients with COVID-19, and utilization of end-of-life care by cancer patients. In addition, he is an editor for HemOnc.org and theMednet, a physician-only online community where members share clinical questions and answers.

  • Saad A. Khan, MD

    Saad A. Khan, MD

    Assistant Professor of Medicine (Oncology)

    BioDr. Khan is a fellowship-trained cancer specialist with board certification in oncology and hematology. He is an assistant professor in the Department of Medicine, Division of Oncology.

    Dr. Khan focuses on the treatment of head and neck cancers, advanced thyroid cancers, and neuroendocrine tumors. He recognizes the broad effects of these conditions on daily living and aims to develop personalized, comprehensive treatment plans that optimize health and quality of life.

    Dr. Khan’s research interests include therapeutic clinical trials as well as ways to reduce toxicities that some patients may experience when receiving cancer treatment. His research activities include ongoing clinical trials of targeted and immune therapy for aggressive thyroid cancer.

    He has published numerous articles on his research discoveries in peer-reviewed journals such as the JAMA Oncology, Investigational New Drugs, and others. Topics include new drug treatments for small cell lung cancer and for cancers of the head and neck, racial and gender disparities in certain types of cancer, and management of the potentially toxic effects of cancer therapies.

    Dr. Khan is a member of the NRG Head and Neck Committee. NRG brings together internationally recognized groups (the first words in their names form the acronym “NRG”) to conduct cancer clinical research and share study results. The objective is to inform clinical decision making and healthcare policy worldwide.

    Dr. Khan is a member of the ECOG Head and Neck Core and Thoracic Committees. ECOG (Eastern Cooperative Oncology Group) is part of one of the five groups of the National Cancer Institute (NCI) National Clinical Trials Network (NCTN) Program.

    He also is a member of the National Cancer Institute’s Central IRB for Early Phase Clinical Trials.

    When not providing patient care or conducting research, Dr. Khan enjoys spending time with his family, hiking, and relaxing at the beach.

  • Youn H Kim, MD

    Youn H Kim, MD

    The Joanne and Peter Haas, Jr., Professor for Cutaneous Lymphoma Research and Professor, by courtesy, of Medicine (Oncology)

    Current Research and Scholarly InterestsClinical research in cutaneous lymphomas, especially, mycosis fungoides; studies of prognostic factors, long-term survival results, and effects of therapies. Collaborative research with Departments of Pathology and Oncology in basic mechanisms of cutaneous lymphomas. Clinical trials of new investigative therapies for various dermatologic conditions or clinical trials of known therapies for new indications.

  • Allison W. Kurian, M.D., M.Sc.

    Allison W. Kurian, M.D., M.Sc.

    Professor of Medicine (Oncology) and of Epidemiology and Population Health

    Current Research and Scholarly InterestsI aim to understand cancer burden and improve treatment quality at the population level. I have a strong focus on genetic risk assessment and precision oncology. I lead epidemiologic studies of cancer risk factors, clinical trials of novel approaches to cancer risk reduction, and decision analyses of strategies to optimize cancer outcomes.

  • David Kurtz

    David Kurtz

    Assistant Professor of Medicine (Oncology)

    Current Research and Scholarly InterestsImplementation of noninvasive detection of malignancies in the clinic remains difficult due to both technical and clinical challenges. These include necessary improvements in sensitivity and specificity of biomarkers, as well as demonstration of clinical utility of these assays. My research focuses on technical development and implementation of assays to detect and track cancers in order to facilitate personalized disease management.

  • HoJoon Lee

    HoJoon Lee

    Sr Biomedical Data Scientist, Medicine - Med/Oncology

    Current Role at StanfordSenior Data Scientist

  • Ronald Levy, MD

    Ronald Levy, MD

    Robert K. and Helen K. Summy Professor in the School of Medicine

    Current Research and Scholarly InterestsClinical Interests: lymphoma. Research Interests: Immunology and molecular biology of lymphoid malignancy; molecular vaccines for cancer.

  • Michael Lim, M.D.

    Michael Lim, M.D.

    Professor of Neurosurgery and, by courtesy, of Radiation Oncology (Radiation Therapy), of Medicine (Oncology), of Otolaryngology - Head & Neck Surgery (OHNS) and of Neurology

    BioDr. Lim is the Chair of the Department of Neurosurgery and a board-certified neurosurgeon specializing in brain tumors and trigeminal neuralgia.

    Dr. Lim’s clinical interests include the treatment of benign and malignant brain tumors, with special interest in gliomas, meningiomas, metastatic tumors, and skull base tumors. Dr. Lim also specializes in surgical treatments for trigeminal neuralgia. During his time at Johns Hopkins, Dr. Lim built one of the largest brain tumor and trigeminal neuralgia practices and utilized the most advanced surgical technologies and techniques for his patients. As a passionate voice for patient experience, he has been recognized by his peers and patients for his integrity and compassionate care, including a Service Excellence Award from HealthNetwork Foundation.

    As a mentor, he has garnered numerous teaching awards, including being honored as an outstanding teacher by Johns Hopkins University School of Medicine. He is actively involved in shaping education for neurosurgery and oncology across the United States and around the world.

    Dr. Lim’s research interests focus on harnessing the immune system to fight cancer. His laboratory focuses on understanding mechanisms of immune evasion by cancer cells. He has successfully translated his findings from the laboratory to the clinics and has conducted and led several large national immunotherapy clinical trials for brain tumors.

    Dr. Lim’s bibliography contains well over 200 articles on topics such as immunotherapy for glioblastoma, long-term survival of glioma patients treated with stereotactic radiation, and treatment of neuropathic pain. His work has appeared in Science Translational Medicine, Clinical Cancer Research, Lancet Oncology, Nature Immunology, and many more publications. He also has written 20 book chapters and monographs.

    Dr. Lim is a world leader in immunotherapy for brain tumors. In addition to being invited world-wide to give lectures and seminars, he has given platform presentations on the topics of immunotherapy for brain tumors, neurosurgical techniques and management of brain tumors at the American Society of Clinical Oncologists, American Academy of Neurological Surgeons, Radiological Society of North America, Annual Symposium on Brain and Spine Metastases, Congress of Neurological Surgeons, and other meetings. In addition, he has served as platform chairman of the CNS session at the American Society for Clinical Oncology conference.

    Dr. Lim is a member of the American Society for Clinical Oncology, Congress of Neurological Surgeons, American Association of Neurological Surgeons, and Society for Neuro-Oncology. Dr. Lim served as the program co-chair of the Society for Neuro-Oncology and CNS section of the American Society for Clinical Oncology. He also served on many executive committees, including the Executive Committee for the Joint Tumor Section of the American Association of Neurological Surgeons and Congress of Neurological Surgeons.

  • Beverly S. Mitchell, M.D.

    Beverly S. Mitchell, M.D.

    George E. Becker Professor of Medicine and Professor, by courtesy, of Chemical and Systems Biology

    Current Research and Scholarly InterestsBeverly Mitchell's research relates to the development of new therapies for hematologic malignancies, including leukemias and myelodsyplastic syndromes. She is interested in preclinical proof of principle studies on mechanisms inducing cell death and on metabolic targets involving nucleic acid biosynthesis in malignant cells. She is also interested in the translation of these studies into clinical trials.

  • Eric Mou, MD

    Eric Mou, MD

    Postdoctoral Medical Fellow, Oncology

    BioI was born in Oregon and raised in Iowa, where I cultivated my initial interest in science and medicine. I completed my undergraduate degree and medical school at the University of Iowa before heading to Stanford University for my internal medicine residency and oncology fellowship training. I chose this field to try my best in assisting patients during times of great need, and working to understand what is of greatest importance to them as they navigate their unique journey of cancer care. My clinical focus is in the care of patients with lymphoma and other hematologic cancers. My scholarly interests include better understanding the efficacy cancer therapeutics, improving patients' experience as the proceed through treatment, and promoting strength in medical education.

  • Joel Neal, MD, PhD

    Joel Neal, MD, PhD

    Associate Professor of Medicine (Oncology)

    Current Research and Scholarly InterestsI am a thoracic oncologist who cares for patients with non-small cell lung cancer, malignant mesothelioma, and other thoracic malignancies. I design and conduct clinical trials of novel therapies in collaboration with other researchers and pharmaceutical companies. These generally focus on two areas, 1) targeted therapies against particular mutations in cancers (for example EGFR, ALK, ROS1, HER2, KRAS, MET, and others) and 2) the emerging field of immunotherapy in cancer, using anti PD-1/PD-L1 therapies in combination with other agents, and also developing cellular therapies. I also collaborate with other researchers on campus to apply emerging technologies to cancer therapy, for example, circulating tumor DNA detection. Additionally, in my role as the Cancer Center IT Medical Director, I coordinate projects relating to our use of the electronic health record to improve provider efficiency and facilitate patient care.